SAFINAMIDE (Xadago®)
Clinical Indication
Parkinson’s Disease
Date of classification
August 2018
Review date
August 2021
Amber SIMPLE
Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.